"Designing Growth Strategies is in our DNA"

Pulmonary Arterial Hypertension (PAH) Treatment Market Size, Share and Global Trend By Drug Class (Soluble Guanylate Cyclase (SGC) Stimulators,Prostacyclin and Prostacyclin Analogs, Phosphodiesterase 5 (PDE-5), Endothelin Receptor Antagonists (ERA)), By End User (Hospitals, Clinics, Others), and Geography Forecast till 2022-2029

Region : Global | Report ID: FBI101003 | Status : Ongoing

 

KEY MARKET INSIGHTS

Pulmonary arterial hypertension (PAH) is a chronic, progressive disease defined by increasing pulmonary vascular resistance and pulmonary arterial pressure, ultimately leading to heart failure. Symptoms of pulmonary arterial hypertension (PAH) include shortness of breath (dyspnea) during exercise, chest pain, and fainting episodes. The exact cause of pulmonary arterial hypertension (PAH) is unknown and although treatable, there is no known cure for this disease.

PAH usually affects women between the ages of 30-60. According to the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO), the new cases are estimated to occur in one to two individuals per million each year in the U.S.

To gain extensive insights into the market, Request for Customization


The increasing prevalence of pulmonary arterial hypertension (PAH) due to causative diseases including lung diseases, human immunodeficiency virus (HIV) infection, connective tissue disorders, chronic liver diseases, and other conditions are some of the factors driving the growth of the global pulmonary arterial hypertension (PAH) market. Additionally, increasing adoption of the sedentary lifestyle, rising consumption of alcohol, and increased smoking prevalence among adults are factors presenting a large patient pool suffering from pulmonary arterial hypertension globally. 


However, the high cost of the treatment of pulmonary arterial hypertension is a major factor restraining the growth of the global pulmonary arterial hypertension (PAH) treatment market.


Key Players Covered


Some of the major companies that are present in the global pulmonary arterial hypertension (PAH) treatment market are Actelion Pharmaceuticals Ltd., Gilead Sciences Inc., Pfizer Inc., GlaxoSmithKline Plc., Novartis AG, Bayer AG, United Therapeutics Corp, and others.


SEGMENTATION






















SEGMENTATION



 DETAILS



By Drug Class



· Soluble Guanylate Cyclase (SGC) Stimulators


· Prostacyclin and Prostacyclin Analogs


· Phosphodiesterase 5 (PDE-5)


· Endothelin Receptor Antagonists (ERA)



By End-User



· Hospitals


· Clinics


· Others



By Geography



· North America (the USA and Canada)


· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)


· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)


· Latin America (Brazil, Mexico and Rest of Latin America)


· Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)



 


In 2018, among drug class, prostacyclin and prostacyclin analogs dominated the global pulmonary arterial hypertension (PAH) treatment market owing to the development in oral prostacyclin agents, leading to the introduction of more efficient drugs such as Orenitram and Uptravi. This segment is projected to grow at comparatively higher CAGR during the forecast period.


Key Insights



  • Prvalance of Pulmonary Arterial Hypertension (PAH) Key Countries/Region

  • Pipeline Analysis, Key Players

  • Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions


Regional Analysis


North America accounted for the largest market share of the global pulmonary arterial hypertension (PAH) treatment market in 2018. Rising prevalence of cardiovascular diseases combined with the increasing number of regulatory approvals being granted to new treatment medications are some of the factors driving the growth of the pulmonary arterial hypertension (PAH) treatment market in North America. Additionally, supportive legislation like the Rare Disease Act 2002 and the Orphan Drug Act (ODA) 1983 in the U.S. aided the development of novel medication for pulmonary arterial hypertension in the region.


Key Industry Developments



  • In May 2019, Teva Pharmaceutical Industries Ltd., launched generic version of Gilead’s Letairis (ambrisentan) tablets in the United States. Ambrisentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH).
  • In Sepember 2017, Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, received U.S. Food and Drug Administration (FDA) has approved a new 32 mg tablet for oral suspension for TRACLEER (bosentan) for use in pediatric patients aged three years and older with idiopathic or congenital pulmonary arterial hypertension (PAH).

  • Ongoing
  • 2021
  • 2018-2020

    CHOOSE LICENSE TYPE

  • $4850
    $5850
    $7850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

uniliver
Grifols
Roche
abbvie
Galemed

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X